Antifungal drug tested against brain tumors – trial stopped early
NCT ID NCT03796273
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This early-phase trial tested whether the antifungal drug ketoconazole could block a protein called tGLI1 in brain tumors. It included 15 people with breast cancer that spread to the brain or with a type of brain cancer called glioma. The study was terminated early, so we have limited information on whether the drug worked or was safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ketoconazole
- What this could lead to
- If it had worked, this could have pointed toward a new way to treat brain tumors by targeting a specific protein.
- What could go wrong
- This was a very early, small trial that was terminated before completion, so we don't have enough data to know if it works or is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a virus injected into brain tumors fight recurrence?
- Fasting during chemo: a new way to boost treatment?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can adding lenvatinib to standard care outsmart a tough brain cancer?
- Can a sharper beam of radiation shield the mind during brain tumor treatment?
- Digital therapy aims to tame the fear that haunts cancer survivors